## Abstract When health effects can be valued in monetary terms, as in costโbenefit analysis, they should be discounted at the same rate as costs. If health effects are measured in quantities (e.g. quality adjusted life years) as in costโeffectiveness analysis (CEA) and the value of health effects
DISCOUNTING HEALTH AND COST-EFFECTIVENESS ANALYSIS: A RESPONSE TO NORD
โ Scribed by James K. Hammitt
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 61 KB
- Volume
- 21
- Category
- Article
- ISSN
- 1057-9230
- DOI
- 10.1002/hec.1782
No coin nor oath required. For personal study only.
โฆ Synopsis
SUMMARY
Nord (2011) criticizes standard arguments which assert that consistency requires that future health benefits must be discounted at the same rate as future costs in costโeffectiveness analysis (CEA). He suggests these arguments are misguided because they require transitivity of preferences across decision contexts and that it can be appropriate to discount health at different rates depending on the programs to be compared. I claim that rejecting transitivity is unwarranted and would sharply diminish the utility of CEA. Factors that tempt Nord to reject consistency can be accommodated by recognizing that CEA does not perfectly mimic normative social preferences because it omits factors (like distribution of health in a population) that can be normatively significant. A better approach is to maintain consistency in application of CEA but authorize decision makers to depart from rankings implied by CEA when justified and to explain which specific factors justify the decision. Finally, the assertion that health must be discounted at the same rate as costs requires the additional assumption that the dollar value of health does not change over time, a point that is not always recognized in standard arguments. Copyright ยฉ 2011 John Wiley & Sons, Ltd.
๐ SIMILAR VOLUMES
## Abstract Brouwer and colleagues [1] argue that the reasons for specifying an equal discount rate for health outcomes and costs in the recent guidance on methods of technology appraisal issued by the National Institute for Clinical Excellence (NICE) [2] is both opaque and wrong. They argue that a
## Abstract We argue that health programs are administered in settings that often violate the frequently stated assumption of constant returns to scale in the provision of health services. Three types of returns to scale are identified from the general economic literature: returns to scale with res
## Abstract The inclusion of economic evaluations as part of clinical trials has led to concerns about the adequacy of trial sample size to support such analysis. The analytical tool of costโeffectiveness analysis is the incremental costโeffectiveness ratio (ICER), which is compared with a threshol
A recent paper in this journal by Sculpher and Gafni (henceforth S&G), argues for the use of 'preference sub-groups' in determining health state utilities values for use in cost-effectiveness analyses [1]. S&G adopt as a starting point the suggestion that the source of utilities should be the genera